Literature DB >> 9874457

Medical audit after 26,711 breast imaging studies: improved rate of detection of small breast carcinomas (classified as Tis or T1a,b)

F Schmidt1, K A Hartwagner, E B Spork, R Groell.   

Abstract

BACKGROUND: Patients with breast carcinomas 1 cm or smaller are known to have the highest long term survival rates. This pathologic measurement was used as a quality indicator of the performance of different reporting radiologists.
METHODS: A total of 26,711 diagnostic breast imaging studies were performed over a period of 5 years. Within the first 18 months, several general radiologists reported mammograms, whereas during the rest of the evaluated period only 1 radiologist was responsible for all mammography reporting. Radiologic findings leading to open biopsy were correlated with the histologic results. The cancer sizes from the histologic reports were recorded, and the number of Tis, T1a, and T1b cancers were correlated with all cancers found at open biopsy. The change in the relative percentage of small cancers was evaluated, along with the positive predictive value (PPV).
RESULTS: Between 1991 and 1995, 26,711 breast imaging studies were performed. This resulted in 2698 open biopsies with 620 breast carcinomas detected. In the first 2 years, the percentages of small cancers detected (Tis or T1a,b) were 27.2% and 25.7%, respectively. In the third, fourth, and fifth years, the percentages increased to 38.8%, 34.5%, and 38.8%, respectively. At the same time, the PPV increased slightly, from 0.23 in 1991 to 0.27 in 1995.
CONCLUSIONS: The detection of curable early stage breast carcinomas requires the dedication and commitment of a small group of radiologists who are willing to spend most of their time on this single subject. This will increase considerably the number of early stage cancers found and reduce the number of false-positive diagnoses. [See editorial counterpoint on pages 2430-1 and reply to counterpoint on pages 2432-3.]

Entities:  

Mesh:

Year:  1998        PMID: 9874457     DOI: 10.1002/(sici)1097-0142(19981215)83:12<2516::aid-cncr16>3.0.co;2-#

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  6 in total

1.  Mortality from breast carcinoma among US women: the role and implications of socio-economics, heterogeneous insurance, screening mammography, and geography.

Authors:  Albert A Okunade; Mustafa C Karakus
Journal:  Health Care Manag Sci       Date:  2003-11

2.  Dedicated screening mammography for diagnosis of small breast cancer.

Authors:  Boris Kirshtein; Pavel Crystal; Michael Koretz; Selwyn Strano
Journal:  World J Surg       Date:  2004-02-17       Impact factor: 3.352

3.  Exploring the use and impact of adjuvant trastuzumab for HER2-positive breast cancer patients in a large UK cancer network. Do the results of international clinical trials translate into a similar benefit for patients in South East Wales?

Authors:  R M Webster; J Abraham; N Palaniappan; A Caley; B Jasani; P Barrett-Lee
Journal:  Br J Cancer       Date:  2011-11-22       Impact factor: 7.640

4.  Clinical Overestimation of HER2 Positivity in Early Estrogen and Progesterone Receptor-Positive Breast Cancer and the Value of Molecular Subtyping Using BluePrint.

Authors:  Ettienne J Myburgh; Lizanne Langenhoven; Kathleen A Grant; Lize van der Merwe; Maritha J Kotze
Journal:  J Glob Oncol       Date:  2016-11-16

5.  Survival Outcome and Impact of Chemotherapy in T1 Node-Negative Triple-Negative Breast Cancer: A SEER Database Analysis.

Authors:  Jingyi Zhang; Wenna Wang; Jiayu Wang; Yang Luo; Shanshan Chen; Fei Ma; Binghe Xu; Ying Fan
Journal:  J Oncol       Date:  2020-12-10       Impact factor: 4.375

6.  The Promher Study: An Observational Italian Study on Adjuvant Therapy for HER2-Positive, pT1a-b pN0 Breast Cancer.

Authors:  Stefania Gori; Alessandro Inno; Elena Fiorio; Jennifer Foglietta; Antonella Ferro; Marcella Gulisano; Graziella Pinotti; Marta Gubiotti; Maria Giovanna Cavazzini; Monica Turazza; Simona Duranti; Valeria De Simone; Laura Iezzi; Giancarlo Bisagni; Simon Spazzapan; Luigi Cavanna; Chiara Saggia; Emilio Bria; Elisabetta Cretella; Patrizia Vici; Daniele Santini; Alessandra Fabi; Ornella Garrone; Antonio Frassoldati; Laura Amaducci; Silvana Saracchini; Lucia Evangelisti; Sandro Barni; Teresa Gamucci; Lucia Mentuccia; Lucio Laudadio; Alessandra Zoboli; Fabiana Marchetti; Giuseppe Bogina; Gianluigi Lunardi; Luca Boni
Journal:  PLoS One       Date:  2015-09-04       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.